Clinical Trial Update: Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease [Phase 2]

View source ↗

Summary

Phase 2 study update showing efficacy and safety results for HMR1766 in patients with Fontaine Stage II peripheral arterial disease presenting intermittent clau…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Arterial Disease

Drugs mentioned

• HMR1766

Snippet

Sponsor: Sanofi | Conditions: Intermittent Claudication | Phase 2 | Status: COMPLETED